Gain Therapeutics Inc (GANX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.76 (-1.12%), Market cap $0.08B, 52-week low–high $1.44 ~ $4.18.
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinica
Financial statements, price targets, institutional (13F) holdings and related news for Gain Therapeutics Inc are updated in real time on BlackAll Trade.
Gain Therapeutics Inc trades at $1.76 (-1.12%). Real-time quotes and charts are available on BlackAll Trade.
Gain Therapeutics Inc has a market cap of about $0.08B.
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia.